462 Progression-free survival 2-progression-free survival 1 in patients with primary advanced/recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

Carolyn Mccourt,Graziana Ronzino,Mark S Shahin,Rebecca Kristeleit, Lyndsay Willmott, Oleksandr Zub,Joyce N Barlin,Lucy Gilbert, Noelle Cloven,Line Bjørge,Destin Black, Machteld Wymenga, Sudarshan Sharma,Michael A Gold,Lisa Landrum,Cara Mathews,Grace Antony, Shadi Stevens,Matthew A Powell,Mansoor Raza Mirza

Oral Sessions(2024)

引用 0|浏览4
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要